Correlation Between Pieris Pharmaceuticals and Aceragen

Can any of the company-specific risk be diversified away by investing in both Pieris Pharmaceuticals and Aceragen at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pieris Pharmaceuticals and Aceragen into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Pieris Pharmaceuticals and Aceragen, you can compare the effects of market volatilities on Pieris Pharmaceuticals and Aceragen and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pieris Pharmaceuticals with a short position of Aceragen. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pieris Pharmaceuticals and Aceragen.

Diversification Opportunities for Pieris Pharmaceuticals and Aceragen

0.25

Correlation Coefficient

Pieris Pharmaceuticals  Aceragen

Modest diversification

The 3 months correlation between Pieris and Aceragen is 0.25. Overlapping area represents the amount of risk that can be diversified away by holding Pieris Pharmaceuticals and Aceragen in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Aceragen and Pieris Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pieris Pharmaceuticals are associated (or correlated) with Aceragen. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Aceragen has no effect on the direction of Pieris Pharmaceuticals i.e., Pieris Pharmaceuticals and Aceragen go up and down completely randomly.

Pair Corralation between Pieris Pharmaceuticals and Aceragen

Given the investment horizon of 90 days Pieris Pharmaceuticals is expected to generate 0.67 times more return on investment than Aceragen. However, Pieris Pharmaceuticals is 1.48 times less risky than Aceragen. It trades about -0.02 of its potential returns per unit of risk. Aceragen is currently generating about -0.11 per unit of risk. If you would invest  10,000  in Pieris Pharmaceuticals on October 7, 2024 and sell it today you would lose (8,640) from holding Pieris Pharmaceuticals or give up 86.4% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	27.12%
Values	Daily Returns

Pieris Pharmaceuticals  vs.  Aceragen

Pieris Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Pieris Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in February 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Aceragen

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Aceragen has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, Aceragen is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors.

Pair Trading with Pieris Pharmaceuticals and Aceragen

The main advantage of trading using opposite Pieris Pharmaceuticals and Aceragen positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pieris Pharmaceuticals position performs unexpectedly, Aceragen can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aceragen will offset losses from the drop in Aceragen's long position.

The idea behind Pieris Pharmaceuticals and Aceragen pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.